. 2022 Nov 23;65(23):15789–15804. doi: 10.1021/acs.jmedchem.2c01348

Table 4. Cytotoxic Activity of 3′-dA and Compounds 7a–f, 9^a.

	HepG2		MCF-7		BxPC-3		HT29		MIA PaCa-2		SW620
comp	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%	lC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%
3′-dA	142.47	66	34.23	78	>198	22	>198	44	>198	35	>198	10
7a	18.73	76	3.07	94	23.59	81	13.42	93	6.85	96	24.94	85
Sp-7a	57.0	73	5.87	94	99.0	73	25.0	95	18.0	94	35.0	87
Rp-7a	32.0	78	2.94	97	74.0	71	16.0	97	14.0	96	29.0	82
7b	11.53	95	1.39	99	13.36	90	7.52	98	3.73	98	11.41	93
7c	142.35	59	15.46	87	-	-	-	-	-	-	-	-
7d	9.53	99	2.48	100	65.46	99	16.06	99	14.69	106	35.48	100
7e	96.11	59	15.78	78	60.92	78	25.24	89	12.09	101	43.4	90
7f	70.22	84	9.10	99	76.18	71	37.94	76	17.55	91	56.48	74
9	156.87	55	12.97	97	-	-	-	-	-	-	-	-
PTX	#intersect	54	0.003	79	>0.5	42	0.004	75	0.002	87	0.02	96

Cytotoxicity data reported as μM LC₅₀ values (concentration of drug causing 50% cell death) and MI% values (maximum inhibitory effect of the drug at the range of concentrations considered). PTX: paclitaxel (control); (-) not tested.

Table 4. Cytotoxic Activity of 3′-dA and Compounds 7a–f, 9a.

Table 4. Cytotoxic Activity of 3′-dA and Compounds 7a–f, 9^a.